Peptide Insider

Retatrutide Side Effects: What the Trials Actually Measured

Retatrutide side effects — what the trials actually measured

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

Retatrutide side effects have been measured in more people, for longer, and in more indications than almost any research-market compound: a 338-person, 48-week phase 2 obesity trial in the New England Journal of Medicine, a 281-person type 2 diabetes phase 2 in The Lancet, a 98-person liver-fat substudy, and — as of 2026 — a 537-person phase 3. The short answer: the side effects are gastrointestinal, dose-related, mostly mild to moderate, and softened but not removed by starting low. What separates retatrutide from a plain GLP-1 is a dose-dependent rise in heart rate that peaked at 24 weeks and then declined. This page gives you the actual rates, with citations, and flags where the trial data stops applying to a research vial.

Quick Answer: The Most Common Retatrutide Side Effects

Gastrointestinal events — nausea, diarrhea, vomiting, constipation — led every retatrutide trial. In the type 2 diabetes phase 2, mild-to-moderate GI adverse events were reported in 35% of retatrutide participants, from 13% at 0.5 mg to 50% in the 8 mg fast-escalation group, versus 13% on placebo and 35% on dulaglutide. In the 48-week obesity phase 2, GI events were dose-related, mostly mild to moderate, and partially mitigated by a 2 mg starting dose; heart rate rose dose-dependently, peaking at 24 weeks. In the phase 3, 2–5% of retatrutide participants stopped for adverse events versus 0% on placebo. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience of 1,150+ Trial Participants

The most complete “user experience” of retatrutide belongs to the people who took it under observation — 338 in the obesity phase 2, 281 in the diabetes phase 2, 537 in the phase 3. The typical arc: weight fell steeply through 48 weeks (the 12 mg obesity group averaged a 24.2% reduction), GI effects arrived with the dose and were worst in groups that started high, and — in the phase 3 investigators’ words — “subsided over time.”

How tolerable did participants find it? In the phase 3, 91% completed treatment on study drug and 2–5% discontinued for adverse events; the diabetes phase 2 reported no deaths and no severe hypoglycemia. Placebo groups reported GI events too — 13% in the diabetes trial — a baseline most online discussion never subtracts.

What that experience came with: screening, monitoring, pharmaceutical-grade product from Eli Lilly, and clinician-managed dose escalation — none of which ships with a research vial.

Compiled from the published trials (PMID 37366315, PMID 37385280, PMID 42250575) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is Retatrutide?

Retatrutide (Eli Lilly’s LY3437943) is a single peptide that activates three receptors — GIP, GLP-1, and glucagon — given as a once-weekly subcutaneous injection (PMID 37366315). It is the compound behind the most-quoted number in obesity pharmacology: a 24.2% average weight reduction at 48 weeks in the 12 mg group of its phase 2, versus 2.1% on placebo (PMID 37366315). It is also why our retatrutide overview and vendor guide exist — listings arrived long before any regulator did. Retatrutide is not approved anywhere as of this writing; Lilly’s phase 3 program began publishing in 2026 (PMID 42250575). Every vial sold under this name outside a trial is research-market material.

How It Works — and Why Three Receptors Mean Three Sources of Side Effects

Each receptor brings its own biology. GLP-1 agonism slows gastric emptying and suppresses appetite — the source of the GI effects that define the class, covered in our GLP-1 peptide guide. Glucagon agonism raises energy expenditure and clears liver fat — the phase 2a substudy recorded liver-fat reductions of 81.4% and 82.4% at 8 mg and 12 mg (PMID 38858523) — but glucagon also raises heart rate, the root of the obesity trial’s heart-rate finding. The Lancet investigators called the result a safety profile “consistent with GLP-1 receptor agonists and GIP and GLP-1 receptor agonists” (PMID 37385280): a familiar side-effect set, at higher intensity, with one glucagon-specific addition.

KEY TAKEAWAY

Retatrutide’s side effects are the GLP-1 class profile with the volume turned up: GI events softened, not removed, by a lower starting dose, plus a heart-rate rise that peaked at 24 weeks. The network meta-analysis that ranked it first for efficacy also found it “had the highest AE risk” (PMID 40685589).

The Trial Numbers That Matter

Four datasets do the heavy lifting. The obesity phase 2 (NEJM, 2023): 338 adults with a BMI of 30 or higher, or 27 to less than 30 with a weight-related condition, randomized to placebo or retatrutide 1 mg, 4 mg, 8 mg, or 12 mg for 48 weeks (PMID 37366315). The type 2 diabetes phase 2 (The Lancet, 2023): 281 adults at 42 US centers, randomized to placebo, 1.5 mg dulaglutide, or retatrutide 0.5 mg to 12 mg, followed to 36 weeks (PMID 37385280). The MASLD phase 2a substudy (Nature Medicine, 2024): 98 obesity-trial participants with fatty liver (PMID 38858523). The TRANSCEND-T2D-1 phase 3 (The Lancet, 2026): 537 adults with type 2 diabetes at 48 sites in the USA, Mexico, and India, randomized to retatrutide 4 mg, 9 mg, 12 mg, or placebo for 40 weeks (PMID 42250575).

Gastrointestinal Side Effects: The Real Rates

The diabetes phase 2 abstract reports GI rates by arm. Mild-to-moderate GI adverse events — nausea, diarrhea, vomiting, constipation — were reported in 67 of 190 retatrutide participants (35%), from 6 of 47 (13%) in the 0.5 mg group to 12 of 24 (50%) in the 8 mg fast-escalation group, versus 6 of 45 (13%) on placebo and 16 of 46 (35%) on 1.5 mg dulaglutide (PMID 37385280). The placebo floor is 13%, so the lowest dose added nothing attributable; the pooled 35% is identical to dulaglutide’s, an approved GLP-1 at its standard dose; and the 50% ceiling comes from a 24-person arm that escalated fastest, so treat it as noisy.

The obesity phase 2 abstract reports the pattern, not the percentages: GI events were the most common adverse events, “were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg)” (PMID 37366315). No per-arm nausea rates appear in it, so none appear here. The phase 3 abstract is similarly qualitative — “generally mild to moderate gastrointestinal events, which subsided over time” — with 2–5% of retatrutide participants discontinuing for adverse events versus 0% on placebo (PMID 42250575).

PERSONAL OBSERVATION — PI EDITORIAL

Reading these trials side by side, what struck us was how much the headline depends on which abstract you open. The NEJM obesity paper — the one listings quote — says dose-related and mostly mild to moderate, and gives no percentages. The Lancet diabetes paper gives them: 13% to 50%, with placebo and dulaglutide at 13% and 35%. A writeup quoting “24.2% weight loss” and “mostly mild” without that 50% is technically accurate and materially misleading.

Bar chart from the retatrutide type 2 diabetes phase 2 trial: mild-to-moderate gastrointestinal adverse events in 13% on placebo, 35% on dulaglutide 1.5 mg, 13% on retatrutide 0.5 mg, 50% on retatrutide 8 mg fast escalation, and 35% across all retatrutide arms.
Chart: gastrointestinal adverse events by arm in the 36-week type 2 diabetes phase 2, plotted from the published rates (PMID 37385280). The abstract breaks out only the lowest and highest retatrutide arms plus the pooled figure; note the placebo and dulaglutide columns.

Heart Rate: The Side Effect That Sets Retatrutide Apart

The finding that separates retatrutide from a plain GLP-1 is one sentence of the NEJM abstract: “Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter” (PMID 37366315). It scaled with dose, peaked at the trial’s midpoint — so a 24-week snapshot overstates the steady state — and declined while dosing continued. The abstract does not give the size of the increase, a tachycardia rate, or arrhythmia data. Glucagon receptor agonism is the plausible driver — the component GLP-1 monotherapies lack and mazdutide and survodutide share. Neither diabetes-trial abstract mentions heart rate (PMID 37385280, PMID 42250575) — meaning the authors did not headline it, nothing more.

Injection-Site Reactions

None of the four abstracts reports injection-site reaction rates or names administration-site events among the most common adverse events (PMID 37366315, PMID 37385280, PMID 42250575) — which tells you they were not a leading category, and nothing more precise. Retatrutide is injected exactly like its GLP-1 peers, so the standard handling picture applies.

PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING

  • Reconstituted solutions brought to room temperature before use are standard practice in clinical settings
  • Site rotation (abdomen, thigh, upper arm) is how trial protocols manage repeated weekly injections
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
  • Our bacteriostatic water guide covers reconstitution handling in detail

Beyond the Gut: What Else the Trials Recorded

Outside the gut, the abstracts give three hard facts and one silence. Hypoglycemia: none severe in the diabetes phase 2 or the phase 3 — notable in type 2 diabetes populations (PMID 37385280, PMID 42250575). Deaths: none in the diabetes phase 2; two in the phase 3, both in the 4 mg group and judged unrelated to the study drug (PMID 42250575). Liver: the MASLD substudy abstract is pure efficacy — liver fat fell 42.9%, 57.0%, 81.4%, and 82.4% at 1, 4, 8, and 12 mg versus a 0.3% rise on placebo (PMID 38858523) — with no adverse-event data. The silence: no abstract reports pancreatitis, gallbladder events, or mood-related events. Absence from an abstract is not absence from the trial; the full papers’ supplementary tables answer that question.

What Users Report: Self-Reported Effects From Reddit

The trial figures above describe monitored participants on pharmaceutical retatrutide under clinician-managed titration. They say nothing about mood, libido or skin sensation, or about gray-market vials at self-chosen doses. We searched Reddit on September 5, 2026, found 158 relevant posts from 2025 to 2026, and read the comment threads of twelve, eleven on r/Retatrutide and one on r/Peptides. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. Three problems color the record: weekly doses described from a tenth of a milligram to fifteen milligrams, beyond the top trial arm; stacking with testosterone, tirzepatide, cagrilintide or growth-hormone secretagogues; and the two largest threads asking outright for worst or scariest effects.

Emotional flatness is the effect the trials never measured and Reddit discusses most. A poster on about 9 mg a week wrote that he no longer cared about friends, family, partner or work; top replies marveled at how casually anhedonia gets called minor (r/Retatrutide). At least two dozen distinct posters describe the same flatness. Several quit over it, one because it turned him into “a shell on autopilot” (thread). Two said it persisted months after stopping; two others said it resolved in about three months; one noticed it even at 1 mg (thread). A 53-year-old woman quit after a low dose left her flat, dulled and exhausted (r/Peptides). At least seven welcomed it. Libido loss travels with it: at least a dozen describe it, four reported the opposite, one on high-dose testosterone. Commenters often blamed the calorie deficit, not the drug.

Heart rate and anxiety reports match the trial signal, and some ended in a hospital. More than twenty distinct posters describe a racing or elevated heart rate, mostly early and mostly fading. A post about chest and throat tightness that sent its author to hospital after a 0.5 mg dose drew accusations of hypochondria, doubts that the vial was really retatrutide, and a self-described nurse with no anxiety history reporting the worst panic attack of her life (r/Retatrutide). One poster went to the ER for anxiety episodes; another was bed-bound by a resting rate above 125 until his doctor prescribed medication; two said palpitations vanished with more water and electrolytes (thread). One panic episode coincided with both a jump from 2 to 4 mg and a new vendor (thread).

Sunburned skin is a Reddit discovery the trials did not record. Around thirty distinct posters describe allodynia: skin that feels sunburned or bruised, clothes and car seats that hurt, sheets that ruin sleep. Most tie it to a dose increase or an accidental double dose (r/Retatrutide), but two report it at 1 mg or lower, and one has lived with it for eight months. Two describe itching severe enough to break skin, one after switching source (thread). Nobody in these threads reports hair loss.

Gut effects dominate, as in the trials, and the worst come from dose errors. More than forty distinct posters describe nausea, diarrhea, constipation, reflux, bloating or sulfur burps. The most-upvoted thread is a warning from a man who mixed two vials, forgot to relabel, and injected 14 mg: a week of sickness, inability to eat and sunburned skin; replies include an 8 mg injection meant as 2 mg (r/Retatrutide). A woman on 0.5 mg with PCOS and pre-existing gut symptoms asked whether her bloating would pass; nine commenters said theirs had eased (thread). Ten weeks of nausea at 1 mg, a 4 mg first dose producing projectile diarrhea, and a 63-year-old with no side effects share one thread (thread).

Fatigue, insomnia and the break effect round out the picture, alongside people who felt nothing. More than a dozen posters describe early exhaustion, one so severe he stopped training for weeks (r/Retatrutide); a similar number describe insomnia that mostly eased within weeks. After four and a half months of every side effect, a poster skipped two doses on vacation, resumed the same vial and batch, and had none; six commenters reported the same, one the reverse (thread). At least fifteen posters report no or trivial side effects, including a year-long user (thread), and at least six former high-dose tirzepatide users felt nothing at all.

HOW TO READ SELF-REPORTS

Where Reddit and the trials overlap, on gut effects and heart rate, they agree on direction and differ on scale, because posters chose their own doses, often above the trial ceiling. Anhedonia and allodynia have no trial counterpart: nobody asked, so silence in the published record is not reassurance, and their prominence here partly reflects threads that solicited worst experiences. None of this yields a frequency; it yields questions for a phase 3 safety analysis.

When Side Effects Happen — and When They Fade

No published retatrutide data supports a week-by-week side-effect calendar; anyone offering one built it from imagination. What the abstracts establish: the obesity trial’s GI events were “partially mitigated with a lower starting dose” — so the first weeks at any new dose are where events concentrate (PMID 37366315); the phase 3 GI events “subsided over time” across 40 weeks (PMID 42250575); and the heart-rate increase ran on a different clock, peaking at 24 weeks and declining thereafter. Two side effects, two timelines: the gut settles in weeks, the pulse in months. The diabetes trial’s slow and fast 8 mg escalation arms would show how much pacing helped, but the abstract reports only the fast arm’s rate (PMID 37385280).

Long-Term Safety: What 48 Weeks Can and Can’t Tell You

The longest published exposure is 48 weeks in 338 people (PMID 37366315); the phase 3 ran 40 weeks in 537 (PMID 42250575). That is more participant-time than any other compound in this batch — and it is the entire horizon. Nobody has five-year data. A network meta-analysis of 19 randomized trials and 29,506 adults found retatrutide “had the highest AE risk” of the classes compared, alongside by far the largest odds of 15% or greater weight loss (odds ratio 54.6) (PMID 40685589). Superior efficacy “but with a higher AE risk” is the honest long-term picture as of 2026.

Who the Trials Excluded

Trial safety numbers describe trial populations. The obesity phase 2’s BMI criteria are listed under trials; 51.8% of its participants were men (PMID 37366315). The diabetes phase 2 enrolled adults aged 18–75 with HbA1c of 7.0–10.5%, on diet and exercise or stable metformin; the typical participant was 56.2 years old with 8.1 years of diabetes (PMID 37385280). The phase 3 enrolled adults with HbA1c of 7.0–9.5% and BMI of at least 23, with a mean diabetes duration of just 2.5 years (PMID 42250575). Left out: anyone on insulin, anyone under 18, anyone below the BMI thresholds. Every rate here came from screened, monitored people with clinicians watching — the boundary of what these numbers can promise.

Managing and Minimizing Side Effects: What the Trials Did

The trials’ side-effect management was structural — dose selection and escalation design, not add-on fixes. The obesity phase 2 tested 2 mg against 4 mg starting doses; its one management finding is that GI events “were partially mitigated with a lower starting dose (2 mg vs. 4 mg)” (PMID 37366315). Partially. The diabetes phase 2 ran slow and fast 8 mg escalation arms and a 4 mg arm with no escalation (PMID 37385280). No anti-nausea co-medication appears in any abstract. We report this as trial architecture, not a protocol recommendation: the sponsor’s best mitigation reduced the GI burden without removing it.

Dose and Side Effects: The Correlation Is Measured

The dose–effect relationship was mapped across the full dose range. Weight loss at 48 weeks climbed from 8.7% (1 mg) through 17.1% (4 mg) and 22.8% (8 mg) to 24.2% (12 mg), versus 2.1% on placebo (PMID 37366315). Side effects climbed the same ladder: GI events were “dose-related” in the obesity trial, ran 13% to 50% by arm in the diabetes trial, and the heart-rate increase was “dose-dependent.” Notice where the curve bends: 8 mg and 12 mg were close on weight (22.8% vs 24.2%) and liver fat (81.4% vs 82.4%) while side-effect burden kept rising. No published dose separates effect from side effect; there is a visible dose above which effect stops rising as fast.

DID YOU KNOW

The phase 3 program dropped the 8 mg arm for 9 mg: TRANSCEND-T2D-1 tested 4, 9, and 12 mg (PMID 42250575) where the phase 2 trials tested 4, 8, and 12 (PMID 37366315). The Lancet phase 2 authors wrote that their data “informed dose selection for the phase 3 programme” (PMID 37385280).

Retatrutide Alone vs Stacked: What the Data Covers

Every published retatrutide safety number comes from retatrutide alone. No combination trial has been published, so the stacks research forums discuss — retatrutide plus cagrilintide, plus eloralintide — have no human safety data at all. The nearest documented analogy is cagrilintide plus semaglutide, where stacking an amylin on a GLP-1 pushed GI rates well above either alone; our cagrilintide page has those figures. Retatrutide is already three agonists in one molecule, and its monotherapy adverse-event burden already ranks highest in its class (PMID 40685589). Adding a fourth mechanism is an experiment nobody has run under observation. Our GLP-3 sourcing guide covers the market side of that family.

How Retatrutide Compares to Mazdutide, Survodutide, and the GLP-1s

No head-to-head trial pits retatrutide against another next-generation agonist, so every comparison is cross-trial — different populations, durations, doses, and reporting — a real limitation. The only comparator retatrutide has faced inside a trial is 1.5 mg dulaglutide: it matched dulaglutide’s GI rate (35% vs 35%) while producing far more weight loss (16.94% vs 2.02% at 36 weeks) (PMID 37385280). The network meta-analysis found retatrutide and the dual agonists produced equivalent mean weight loss (-11.0 kg), ahead of GLP-1 monoagonists (-9.0 kg), with retatrutide alone carrying the highest adverse-event risk (PMID 40685589). For the glucagon-containing duals — same heart-rate mechanism, no GIP — see mazdutide side effects and survodutide side effects; for the antibody-peptide conjugate, MariTide side effects. Our retatrutide primer covers the receptor pharmacology behind all of them.

Where the Trial Data Stops: The Research-Vial Reality

Everything above describes pharmaceutical-grade LY3437943, made by Eli Lilly, dosed under supervision, with pulse and blood chemistry checked on a schedule. A lyophilized vial from a research-chemical storefront shares a molecule name with that product and nothing else verifiable. The gap shows up three ways: identity and purity (a batch-matched COA is the only evidence the vial contains dose-accurate retatrutide — our lab-testing guide explains what a real one shows), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer — our peptide calculator handles the math), and no medical monitoring, the invisible ingredient in every trial safety table. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

Retatrutide is the most-searched research-market peptide of this cycle, which makes it the most-counterfeited by default. The checklist is unchanged: a batch-matched COA naming compound and quantity, independent third-party testing with a verifiable report number, and hard skepticism toward any listing quoting the NEJM trial’s 24.2% as if it applied to the vial. (Disclosure: some links on this site are affiliate links; they do not change what we report.) Our buy retatrutide online guide tracks which vendors publish documentation, our vendor reviews show what passing paperwork looks like, and our guide library covers verification.

US Regulatory Status

Retatrutide is an investigational compound: not FDA-approved anywhere. Lilly’s phase 3 program is publishing — TRANSCEND-T2D-1 appeared in The Lancet in 2026 (PMID 42250575) — and the direction of travel is toward a prescription product. Until then, every vial in circulation is research-market material sold for non-human research use, and no regulator has evaluated any of those products for identity, purity, or the safety profile above. Our coverage of the FDA’s July 2026 peptide vote tracks the wider regulatory climate. When approval status changes, this section changes with it.

PERSONAL OBSERVATION — PI EDITORIAL

We have watched retatrutide’s search curve since the 2023 papers landed, and in listings we’ve reviewed the pattern holds: the NEJM weight-loss percentages are on the product page, the Lancet GI percentages are not, and the heart-rate sentence appears nowhere. The trial compound was made by one of the most audited manufacturing operations on earth and given to people whose clinicians checked their pulse for 48 weeks. The vial is made by whoever filled a synthesis order. Until third-party testing of market product is routine, the COA is the only sentence of this page that applies to the one in your hand.

If you are converting a retatrutide vial into syringe units, our retatrutide dosage calculator does the arithmetic without suggesting a dose, and lists the trial regimens as context.

Frequently Asked Questions

What are the most common retatrutide side effects?

Gastrointestinal events — nausea, diarrhea, vomiting, constipation. In the type 2 diabetes phase 2, mild-to-moderate GI adverse events affected 35% of retatrutide participants (13% to 50% by arm) versus 13% on placebo and 35% on dulaglutide. In the obesity phase 2 they were dose-related, mostly mild to moderate, and partially mitigated by a lower starting dose.

Does retatrutide raise heart rate?

Yes. The NEJM obesity trial reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter. The abstract does not give the size of the increase; the diabetes trial abstracts do not mention heart rate. Glucagon receptor agonism is the likely mechanism.

How much weight did people lose on retatrutide in trials?

In the 48-week obesity phase 2, 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg) versus 2.1% on placebo. In the 40-week type 2 diabetes phase 3, 11.5%, 13.9%, and 15.3% at 4, 9, and 12 mg versus 2.6%.

Is retatrutide safe?

In trials, adverse events were mostly mild-to-moderate GI events; the diabetes phase 2 reported no severe hypoglycemia and no deaths, the phase 3 two deaths judged unrelated and 2–5% discontinuation for adverse events versus 0% on placebo. A network meta-analysis ranked it highest in its class for adverse-event risk. All measured in screened, monitored people on pharmaceutical-grade product — not research-market vials.

Does a lower starting dose reduce retatrutide side effects?

In the obesity phase 2, GI events were partially mitigated with a 2 mg rather than 4 mg starting dose — partially, not eliminated. We report it as trial architecture, not dosing guidance.

Can you stack retatrutide with cagrilintide or other peptides?

No published human trial has tested retatrutide in any combination. Every published safety number comes from retatrutide alone, which already carries the highest adverse-event risk in its class; any stack’s side-effect profile is unmeasured.

Glossary of Terms

  • Triple agonist: a single molecule that activates three receptors — for retatrutide, GIP, GLP-1, and glucagon.
  • LY3437943: Eli Lilly’s development code for retatrutide, used in early papers and trial registries.
  • GIP (glucose-dependent insulinotropic polypeptide): an incretin hormone; retatrutide’s GIP activity is what mazdutide and survodutide lack.
  • Glucagon receptor agonism: the component that raises energy expenditure and clears liver fat — and the plausible driver of the heart-rate increase.
  • Dose escalation: starting low and stepping up so tolerance develops — the obesity trial compared 2 mg and 4 mg starting doses.
  • MASLD: metabolic dysfunction-associated steatotic liver disease — fatty liver; the phase 2a substudy measured liver-fat change in 98 participants.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.

References